Candidate Selection and Practice Management Considerations With Anticomplement Therapy for GA

Overview

The introduction of anticomplement therapy for geographic atrophy (GA) offers new treatment options for patients previously without effective interventions. However, careful consideration of candidate selection and practice management is essential to accommodate the anticipated increase in patient volume and treatment burden.

Background

Geographic atrophy (GA) is a chronic and progressive form of age-related macular degeneration (AMD) that leads to significant vision loss. The recent approval of anticomplement therapies provides a new avenue for treatment, yet the lack of restrictions on patient eligibility raises concerns about appropriate candidate selection. Understanding the implications of these therapies on clinical practice is crucial for optimizing patient outcomes and managing healthcare resources.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• Anticomplement therapies are now available for all patients with GA secondary to AMD, regardless of visual acuity or lesion characteristics.
• Patient discussions reveal that the status of the fellow eye significantly influences treatment decisions.
• Population estimates suggest a potential influx of GA patients requiring long-term injections, which may overwhelm some practices.
• Practice management considerations include the need for additional staff time for prior authorizations and billing.
• Physical constraints, such as storage for injections, must also be addressed in clinical settings.

Clinical Implications

Clinicians must educate patients about the natural progression of GA and the potential benefits and risks of anticomplement therapy. Additionally, practices should prepare for increased patient volumes and the associated logistical challenges of administering these new treatments.

Conclusion

The advent of anticomplement therapy for GA represents a significant advancement in treatment options, but it necessitates careful planning and patient education to ensure effective implementation in clinical practice.

References

1. Retinal Physician, 2025 -- How I Work With My Patients on Complement Inhibitor Therapy for GA
2. Retinal Physician, 2024 -- Patient Selection, Treatment Options, and Beyond With Complement Cascade Inhibitors for GA
3. Ophthalmology Management, 2026 -- Case Study: Identifying Patients With GA for Complement Inhibition Treatment
4. Retinal Physician, 2025 -- Who Stops GA Therapy—and Why
5. ScienceDirect -- Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go
6. PubMed -- Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE
7. Drug Approval for the Treatment of Geographic Atrophy: How We Got Here and Where We Need to Go - ScienceDirect
8. Pegcetacoplan Treatment for Geographic Atrophy in Age-Related Macular Degeneration Over 36 Months: Data From OAKS, DERBY, and GALE - PubMed